Principal Investigator: Priscilla E. Pemu, MD
Coordinator: Connie Jones, LPN
Phone: 404-752-1133
IRB protocol: # 293008 –ASPREE
Start Date: 01/23/2012 End Date: 12/31/2017
Target Enrollment:
Sponsors:
National Institute of Health(National Heart Lung and Blood Institute, National Institute of Neurological Disorders and Stroke, National Institute of Diabetes, Digestive and Kidney Diseases, National Institute on Aging.)
Lay Summary:
ASPREE- Aspirin in Reducing Events in the Elderly
ASPREE- A double-blinded randomized placebo-controlled primary prevention trial designed to assess whether a daily dose 100mg enteric coated aspirin will extend the duration of life in healthy participants age 65 years or above. The study examines whether the benefits of low dose aspirin outweighs the risk in the prevention of heart disease, stroke certain types of cancer and dementia as well as bleeding from the stomach or brain.